glp-1 receptor agonist weight loss Balancing and muscle in GLP1 therapy Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)
Description
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board
M., Percegona, L
J Card Fail (2006) 12(9):6949
